The Contribution of Clinical Subtype to Survival Differences among Patients with De Novo and Recurrent Metastatic Breast Cancer 

The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Community Cancer Centers.